Regencell Bioscience [RGC] vs United Therapeutics [UTHR] Detailed Stock Comparison
Regencell Bioscience
NASDAQ
Loading...
United Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Regencell Bioscience wins in 3 metrics, United Therapeutics wins in 10 metrics, with 1 ties. United Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regencell Bioscience | United Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1,779.13 | 16.92 | Regencell Bioscience |
| Price-to-Book Ratio | 1,121.43 | 2.68 | United Therapeutics |
| Debt-to-Equity Ratio | 0.00 | 0.00 | Tie |
| PEG Ratio | N/A | 1.77 | N/A |
| EV/EBITDA | -1,913.48 | 10.11 | Regencell Bioscience |
| Profit Margin (TTM) | 0.00% | 40.36% | United Therapeutics |
| Operating Margin (TTM) | 0.00% | 45.64% | United Therapeutics |
| EBITDA Margin (TTM) | N/A | 45.64% | N/A |
| Return on Equity | -47.77% | 19.30% | United Therapeutics |
| Return on Assets (TTM) | -30.65% | 12.96% | United Therapeutics |
| Free Cash Flow (TTM) | $-4.01M | $1.08B | United Therapeutics |
| 1-Year Return | 14,581.82% | 24.59% | Regencell Bioscience |
| Price-to-Sales Ratio (TTM) | N/A | 6.37 | N/A |
| Enterprise Value | $7.64B | $16.14B | United Therapeutics |
| EV/Revenue Ratio | N/A | 5.24 | N/A |
| Gross Profit Margin (TTM) | N/A | 89.03% | N/A |
| Revenue per Share (TTM) | $0 | $69 | United Therapeutics |
| Earnings per Share (Diluted) | $-0.01 | $25.12 | United Therapeutics |
| Beta (Stock Volatility) | 2.15 | 0.62 | United Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Regencell Bioscience vs United Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 2.02% | 6.67% | 25.68% | 55.89% | 2,504.84% | 12,323.08% |
| United Therapeutics | 1.20% | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 14,581.82% | 1,845.78% | 5,667.86% | 5,667.86% | 5,667.86% | 5,667.86% |
| United Therapeutics | 24.59% | 114.46% | 326.34% | 258.80% | 694.13% | 1,312.23% |
News Based Sentiment: Regencell Bioscience vs United Therapeutics
Regencell Bioscience
News based Sentiment: POSITIVE
The month of October 2025 showed positive movement in investor sentiment with a decrease in short interest and a higher-than-average news sentiment score. However, the lack of insider and institutional activity tempers the overall outlook, suggesting a need for continued monitoring.
United Therapeutics
News based Sentiment: MIXED
September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.
Performance & Financial Health Analysis: Regencell Bioscience vs United Therapeutics
| Metric | RGC | UTHR |
|---|---|---|
| Market Information | ||
| Market Cap | $7.64B | $19.33B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 183,082 | 924,001 |
| 90 Day Avg. Volume | 247,494 | 904,024 |
| Last Close | $16.15 | $443.44 |
| 52 Week Range | $0.09 - $83.60 | $266.98 - $444.57 |
| % from 52W High | -80.68% | -0.25% |
| All-Time High | $950.00 (May 30, 2025) | $444.57 (Oct 02, 2025) |
| % from All-Time High | -98.30% | -0.25% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.11% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.40% |
| Operating Margin (TTM) | 0.00% | 0.46% |
| Return on Equity (TTM) | -0.48% | 0.19% |
| Debt to Equity (MRQ) | 0.00 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.01 | $158.65 |
| Cash per Share (MRQ) | N/A | $67.41 |
| Operating Cash Flow (TTM) | $-3,881,392 | $1.37B |
| Levered Free Cash Flow (TTM) | $-4,301,837 | $811.05M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Regencell Bioscience vs United Therapeutics
| Metric | RGC | UTHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1,779.13 | 16.92 |
| Forward P/E | N/A | 15.25 |
| PEG Ratio | N/A | 1.77 |
| Price to Sales (TTM) | N/A | 6.37 |
| Price to Book (MRQ) | 1,121.43 | 2.68 |
| Market Capitalization | ||
| Market Capitalization | $7.64B | $19.33B |
| Enterprise Value | $7.64B | $16.14B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 5.24 |
| Enterprise to EBITDA | -1,913.48 | 10.11 |
| Risk & Other Metrics | ||
| Beta | 2.15 | 0.62 |
| Book Value per Share (MRQ) | $0.01 | $158.65 |
Financial Statements Comparison: Regencell Bioscience vs United Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGC | UTHR |
|---|---|---|
| Revenue/Sales | N/A | $794.40M |
| Cost of Goods Sold | N/A | $92.50M |
| Gross Profit | N/A | $701.90M |
| Research & Development | N/A | $149.00M |
| Operating Income (EBIT) | N/A | $382.80M |
| EBITDA | N/A | $449.40M |
| Pre-Tax Income | N/A | $423.50M |
| Income Tax | N/A | $101.30M |
| Net Income (Profit) | N/A | $322.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGC | UTHR |
|---|---|---|
| Cash & Equivalents | $2.96M | $1.90B |
| Total Current Assets | $8.11M | $3.94B |
| Total Current Liabilities | $193,578 | $721.50M |
| Long-Term Debt | $25,934 | N/A |
| Total Shareholders Equity | $8.22M | $6.81B |
| Retained Earnings | $-21.62M | $7.54B |
| Property, Plant & Equipment | $84,780 | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGC | UTHR |
|---|---|---|
| Operating Cash Flow | N/A | $463.80M |
| Capital Expenditures | N/A | $-74.90M |
| Free Cash Flow | N/A | $386.30M |
| Debt Repayment | N/A | $-100.00M |
| Common Stock Repurchase | N/A | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | RGC | UTHR |
|---|---|---|
| Shares Short | 1.68M | 2.78M |
| Short Ratio | 6.07 | 3.12 |
| Short % of Float | 0.02% | 0.08% |
| Average Daily Volume (10 Day) | 183,082 | 924,001 |
| Average Daily Volume (90 Day) | 247,494 | 904,024 |
| Shares Outstanding | 494.49M | 44.83M |
| Float Shares | 18.43M | 42.01M |
| % Held by Insiders | 0.96% | 0.02% |
| % Held by Institutions | 0.00% | 1.00% |
Dividend Analysis & Yield Comparison: Regencell Bioscience vs United Therapeutics
| Metric | RGC | UTHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |